Search
for
Sort by
Research 481–510 of 773
- Review of Promising Off-Label Use of Deucravacitinib
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Evaluation of Olive Oil-Based Formulations Loaded with Baricitinib for Topical Treatment of Alopecia Areata
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model
- Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood
- Effects of biomaterials derived from germinated hemp seeds for stressed hair stem cells and immune cells
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- Effective treatment of alopecia universalis with oral tofacitinib: A case report
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- The Good and Bad News About New Drugs for Treating Alopecia Areata
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
- Mesenchymal-epidermal interactions in hair follicle cycling and regeneration
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
- Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials